Seoul National University

Precision cancer company Syapse is teaming with Seoul National University Hospital and Asian AWS partner Megazone

In Genome Biology this week: new hot pepper reference genomes, comparison of variant classification algorithms, and more.

Mungyeong mummy

A female mummy showing anatomical signs of atherosclerotic cardiovascular disease was found to carry risky versions of seven heart disease-related SNPs.

Using a combination of genome-wide association and expression quantitative trait loci approaches, investigators uncovered shared and population-specific thyroid cancer risk loci.

The researchers have generated the most contiguous de novo assembly of a human genome to date and plan to use it as a reference for population sequencing projects.

Two teams  independently characterized Cpf1's on-target efficiency and off-target specificity, publishing their results last month.

Researchers detected mutations suspected of decreasing human cell binding when they sequenced several MERS-CoV isolates from last year's outbreak in South Korea.

The company will focus on gaining customers for its custom and pre-defined hybrid capture kits first in Southern California, and then across the US.

NEW YORK (GenomeWeb) – The Institut Pasteur de Montevideo in Uruguay, Seoul National University, and Macrogen have launched the Urugenomes Project. The goal is to discover the genetic basis of different diseases in Uruguay as well as spur genetics research growth in Uruguay.

NEW YORK (GenomeWeb News) – DNA Link, a Korean provider of microarrays for forensic analysis, has partnered with researchers at Seoul National University to identify the victims of a massacre that took place more than 60 years ago.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.